The present study sheds light on previously unrecognized effects of gemcitabine on tumor immune response, modulating ADAM10 and ULBP2 shedding, thus suggesting its use in chemoimmunotherapy against human pancreatic cancer. Here, ULBP2 is linked to pancreatic neoplasm.